$TRUP

Tooth Margaret sold $16K of TRUP

Tooth Margaret (CEO) sold 491 shares of TRUPANION, INC. (TRUP) at $31.84 on 2026-08-25.

Original reporting
SEC EDGAR · Tooth Margaret
Published Aug 26, 2026, 10:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TRUP
Neutral
high confidence
Mentioned
$TRUP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRUPNeutralLow
01

Why it matters

The disclosed sale is modest; investors likely to ignore.

02

Market read

Limited relevance; typical insider transaction with low materiality.

03

What to watch

No significant corporate events accompany the transaction.

Relevance 3/10Novelty 4/10Timing: post-market filing on 2026-08-26

Background

Form 4 filings disclose insider transactions; traders monitor large sales for potential red flags.

Company-level read

Ticker impact

$TRUPNeutralHigh confidence
Context

CEO sold 491 shares for $15,633.44 on 2026-08-25, reducing holdings to 186,952 shares.

Expected impact

Minimal short-term price pressure, no lasting impact.

Evidence & confidence

The sale amount is small relative to total holdings and market cap; typical for insiders and not indicative of negative outlook.

Market effects

None

None

None

Counterpoint

The sale could be a routine liquidity move, not a signal of trouble.

Key entities

  • Tooth Margaret

    CEO of Trupanion, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TRUPMed

Why Trupanion (TRUP) Shares Are Sliding Today

Trupanion (TRUP) shares fell 5.8% after Piper Sandler downgraded the stock to Neutral, citing challenges in the pet insurance market and rising claim costs. The firm lowered its price target to $32 from $45. The stock has seen significant volatility, down 19.6% year-to-date and 35.6% from its 52-week high.

$TRUPHigh

Why is Trupanion stock sliding today?

Trupanion stock fell 6.4% after Piper Sandler downgraded it to Neutral and cut its price target to $32 from $45, citing revenue and margin pressures. Zacks Research also downgraded the stock, amplifying the selloff. The company's shares have retreated from their 52-week high of $46.98, trading near the 52-week low of $21.16.

$TRUPMed

Trupanion (TRUP) Is Up 13.4% After New Vet Partnerships and Q2 Results - Has The Bull Case Changed?

Trupanion reported Q2 2026 results with net income of $6.83 million and updated revenue guidance, and it announced new partnerships and integrations with Digitail and Home To Home. The article links VetDirect Pay and Exam Day coverage to pet-care workflows and discusses margin and subscription growth targets, including projected $2.0 billion revenue and $36.5 million earnings by 2029.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

$TRUPMed

TRUPANION, INC. (TRUP): Results of Operations and Financial Condition

TRUPANION, INC. (TRUP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trupanion Reports Second Quarter 2026 Results Authorizes Share Repurchase Program SEATTLE, WA. August 5, 2026 -- Trupanion , Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the second quarter ended